Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria (Core):~* Patients with transfusional iron overload due to:~* low or intermediate (INT-1) risk Myelodysplastic Syndrome (MDS)determined via International Prognosis Scoring System (IPSS) criteria~* other congenital or acquired anemias excluding B-thalassemia and sickle cell disease~* Lifetime transfusion history of ≥20 unit (approximately 100 mL/kg) of packed red blood cells or showing evidence of iron overload (serum ferritin \>1000 µg/L).~* Able to provide written informed consent~* Life expectancy ≥ 12 months If patient was previously treated with deferiprone, a washout period of one month should occur before the first dose of deferasirox~Inclusion criteria (Extension):~* Patients completing the planned 12-month core study (CICL670A2204).~* Written informed consent obtained from the patient and/or legal guardian on the patient's behalf in accordance with national legislation.~Exclusion criteria (Core and Extension):~* Patients with β-thalassemia, sickle cell disease or myelodysplastic syndrome with an IPSS score being Intermediate-2 or High.~* Patients with serum creatinine \> ULN~* Patients with ALT(SGPT) levels \> 5 x ULN~* Significant proteinuria as indicated by a urinary protein/creatinine ratio \>0.5 mg/mg in a non-first void urine sample on two assessments during the screening period.~* History of HIV positive test result , or of clinical or laboratory evidence of active Hepatitis B or Hepatitis C (HBsAg in the absence of HBsAb OR HCV Ab positive with HCV RNA positive and ALT above the normal range)~* Patients on investigational MDS therapies, including lenalidomide, thalidomide, azacitidine and arsenic trioxide, must have a ≥ 4 week washout period prior to the first dose of study drug.~* Patients with systemic uncontrolled hypertension~* Patients with unstable cardiac disease not controlled by standard medical therapy~* Systemic disease (cardiovascular, renal, hepatic, etc.) which would prevent study treatment~* Pregnancy (as documented in required screening laboratory test) or breast feeding.~* Patients treated with systemic investigational drug within the past 4 weeks or topical investigational drug within the past 7 days~* Other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drug~* Patients being considered by the investigator potentially unreliable and/or not cooperative with regard to the study protocol~* History of hypersensitivity to any of the study drug or excipients~* Sexually active pre-menopausal female patients without adequate contraception. Female patients must use effective contraception or must have undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation or be postmenopausal defined by amenorrhea for at least 12 months.~Other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox (Type: EXPERIMENTAL): Participants received initial dose of 20 milligrams per kilogram (mg/kg) Deferasirox tablets was administered orally once daily (OD) based on the Participants body weight. The dose of Deferasirox was adjusted to either 10 mg/kg or 30 mg/kg based on the volumes of blood transfusions being administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).